TVTX · US market
TRAVERE THERAPEUTICS INC COM
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$5.36bnFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$43.46m
- Latest-quarter run-rate earnings
- -US$139.19m
- Latest fiscal-year earnings
- -US$25.55m
- Trailing revenue
- US$591.33m
- Latest-quarter run-rate revenue
- US$678.34m
- Latest fiscal-year revenue
- US$490.73m
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- PJP · Invesco Pharmaceuticals ETF4.00% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
- HELX · Franklin Genomic Advancements ETF2.59% weight · Holdings dated 30 June 2026
- PTH · Invesco Dorsey Wright Healthcare Momentum ETF2.30% weight · Holdings dated 19 August 2026
- PXSAX · Impax Small Cap Fund Class A1.80% weight · Holdings dated 30 June 2026
- DCZRX · Nomura Small Cap Core Fund Class R61.78% weight · Holdings dated 29 May 2026
- MCGIX · AMG GW&K Small Cap Growth Fund - Class I1.51% weight · Holdings dated 30 April 2026Holdings available · disclosure too old for reliabilityHoldings dated 30 April 2026 are 162 days old, beyond this source’s 155-day reliability limit. Ratios remain available as dated research; calculations are unchanged and are not labelled reliable.
- STSRX · American Beacon Stephens Small Cap Growth Fund R61.50% weight · Holdings dated 30 June 2026
- LSMNX · Loomis Sayles Small/Mid Cap Growth Fund Class N1.45% weight · Holdings dated 30 June 2026
- SSDZX · DWS Small Cap Growth Fund - Class R61.35% weight · Holdings dated 30 June 2026
- XBI · State Street SPDR S&P Biotech ETF1.27% weight · Holdings dated 21 August 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.